<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pfizer Inc &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/pfizer-inc/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Mon, 23 Aug 2021 07:01:21 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Pfizer Inc &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>全球重症肌无力市场研究报告预测至2023年</title>
		<link>https://www.yuanzhezixun.com/quanqiuzhongzhengjiwulishichangyanjiubaogaoyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Tue, 23 Apr 2019 06:33:55 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Alexion Pharmaceuticals]]></category>
		<category><![CDATA[and Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[CSL Behring]]></category>
		<category><![CDATA[GE Healthcare]]></category>
		<category><![CDATA[Grifols S.A.]]></category>
		<category><![CDATA[KONINKLIJKE PHILIPS N.V.]]></category>
		<category><![CDATA[Medtronic PLC]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Shire]]></category>
		<category><![CDATA[重症肌无力]]></category>
		<category><![CDATA[重症肌无力市场]]></category>
		<category><![CDATA[重症肌无力市场报告]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19509</guid>

					<description><![CDATA[重症肌无力（MG）是一种免疫系统神经肌肉疾病，其主要作用是减少AChRs在肌肉终板膜上的会聚。北美和拉丁美洲共同致力于全球重症肌无力市场的发展。与此同时，欧洲和亚太地区在价值方面占据第二和第三位。最近重症肌无力的优势已经显着上升，这促使治疗要求急剧增加。预计全球重症肌无力市场在预计期间（2018-2023）的年增长率为9.61％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>个性化膳食补充剂市场研究报告 &#8211; 全球预测至2023年：市场预计将以6.90％的复合年增长率增长</title>
		<link>https://www.yuanzhezixun.com/gexinghuashanshibuchongjishichangyanjiubaogao-quanqiuyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Fri, 11 Jan 2019 03:05:32 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[食品/饮料]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Amway]]></category>
		<category><![CDATA[Amway (Nutrilite)]]></category>
		<category><![CDATA[Archer Daniels Midland]]></category>
		<category><![CDATA[Bactolac Pharmaceutical Inc.]]></category>
		<category><![CDATA[Balchem Corporation]]></category>
		<category><![CDATA[Bayer AG]]></category>
		<category><![CDATA[Carlyle Group]]></category>
		<category><![CDATA[Danisco]]></category>
		<category><![CDATA[Danone Nutricia]]></category>
		<category><![CDATA[Dietary Supplements]]></category>
		<category><![CDATA[Glanbia]]></category>
		<category><![CDATA[GlaxoSmithKline plc]]></category>
		<category><![CDATA[Herbalife International]]></category>
		<category><![CDATA[Natures Product Inc.]]></category>
		<category><![CDATA[Nestlé Health Science]]></category>
		<category><![CDATA[Personalized Nutrition]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[个性化膳食补充剂]]></category>
		<category><![CDATA[膳食补充剂]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16959</guid>

					<description><![CDATA[在2017 - 2023年预测期间，全球个性化营养膳食补充剂市场预计将以6.90％的复合年增长率增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>自闭症和治疗市场报告 &#8211; 全球预测至2023年</title>
		<link>https://www.yuanzhezixun.com/zibizhenghezhiliaoshichangbaogao-quanqiuyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Fri, 11 Jan 2019 03:02:30 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[ASD]]></category>
		<category><![CDATA[Autism Disorder]]></category>
		<category><![CDATA[Autism treatment]]></category>
		<category><![CDATA[Bristol-Myers Squibb and Otsuka Holdings Co.]]></category>
		<category><![CDATA[Consern Pharma Private Limited]]></category>
		<category><![CDATA[Coronis Partners Ltd.]]></category>
		<category><![CDATA[Curemark LLC]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[Heptares Therapeutics Limited]]></category>
		<category><![CDATA[Intra-Cellular Therapies Inc.]]></category>
		<category><![CDATA[Johnson & Johnson Services]]></category>
		<category><![CDATA[Merck & CO Inc.]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Saniona AB]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Ltd]]></category>
		<category><![CDATA[普遍发育障碍]]></category>
		<category><![CDATA[自闭症]]></category>
		<category><![CDATA[自闭症谱系障碍]]></category>
		<category><![CDATA[阿斯伯格综合症]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16956</guid>

					<description><![CDATA[预计2017 - 2023年期间全球自闭症和治疗市场将以4.37％的复合年增长率增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>全球缺血性坏死市场研究报告 &#8211; 预测到2024年</title>
		<link>https://www.yuanzhezixun.com/quanqiuquexuexinghuaisishichangyanjiubaogao-yucedao2024nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Fri, 23 Nov 2018 03:04:59 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Aurobindo Pharma]]></category>
		<category><![CDATA[Bayer Healthcare AG]]></category>
		<category><![CDATA[Boehringer Ingelheim GmbH]]></category>
		<category><![CDATA[Ethicon Inc.]]></category>
		<category><![CDATA[Grifols SA]]></category>
		<category><![CDATA[Integra Life Sciences Corporation]]></category>
		<category><![CDATA[Medtronic PLC]]></category>
		<category><![CDATA[Merck KGaA]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Smith & Nephew]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[Wright Medical Group N.V.]]></category>
		<category><![CDATA[Zimmer Biomet Holdings]]></category>
		<category><![CDATA[缺血性坏死]]></category>
		<category><![CDATA[骨坏死]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16655</guid>

					<description><![CDATA[预计到2024年全球缺血性坏死市场将从2017年的6.996亿美元达到市场价值10.871亿美元，预计2018年至2024年期间的复合年增长率将达到6.58％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
